TY - JOUR
T1 - Therapeutic applications of curcumin nanomedicine formulations in cardiovascular diseases
AU - Salehi, Bahare
AU - Del Prado-Audelo, María L.
AU - Cortés, Hernán
AU - Leyva-gómez, Gerardo
AU - Stojanović-radić, Zorica
AU - Singh, Yengkhom Disco
AU - Patra, Jayanta Kumar
AU - Das, Gitishree
AU - Martins, Natália
AU - Martorell, Miquel
AU - Sharifi-rad, Marzieh
AU - Cho, William C.
AU - Sharifi-rad, Javad
N1 - Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/3
Y1 - 2020/3
N2 - Cardiovascular diseases (CVD) compromises a group of heart and blood vessels disorders with high impact on human health and wellbeing. Curcumin (CUR) have demonstrated beneficial effects on these group of diseases that represent a global burden with a prevalence that continues increasing progressively. Pre- and clinical studies have demonstrated the CUR effects in CVD through its anti-hypercholesterolemic and anti-atherosclerotic effects and its protective properties against cardiac ischemia and reperfusion. However, the CUR therapeutic limitation is its bioavailability. New CUR nanomedicine formulations are developed to solve this problem. The present article aims to discuss different studies and approaches looking into the promising role of nanotechnology-based drug delivery systems to deliver CUR and its derivatives in CVD treatment, with an emphasis on their formulation properties, experimental evidence, bioactivity, as well as challenges and opportunities in developing these systems.
AB - Cardiovascular diseases (CVD) compromises a group of heart and blood vessels disorders with high impact on human health and wellbeing. Curcumin (CUR) have demonstrated beneficial effects on these group of diseases that represent a global burden with a prevalence that continues increasing progressively. Pre- and clinical studies have demonstrated the CUR effects in CVD through its anti-hypercholesterolemic and anti-atherosclerotic effects and its protective properties against cardiac ischemia and reperfusion. However, the CUR therapeutic limitation is its bioavailability. New CUR nanomedicine formulations are developed to solve this problem. The present article aims to discuss different studies and approaches looking into the promising role of nanotechnology-based drug delivery systems to deliver CUR and its derivatives in CVD treatment, with an emphasis on their formulation properties, experimental evidence, bioactivity, as well as challenges and opportunities in developing these systems.
KW - Cardiovascular disease
KW - Curcumin
KW - Liposome
KW - Nanocurcumin
KW - Nanoformulation
KW - Nanomedicine
UR - http://www.scopus.com/inward/record.url?scp=85083999431&partnerID=8YFLogxK
U2 - 10.3390/jcm9030746
DO - 10.3390/jcm9030746
M3 - Review article
AN - SCOPUS:85083999431
SN - 2077-0383
VL - 9
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 3
M1 - 746
ER -